Cephapirin Sodium

CHEMBL1201043 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
445.4 g/mol
LogP
Phase
4

The sodium salt form of cephapirin was used parenterally for gram-positive bacterial infections and surgical prophylaxis in human medicine. As an early first-generation cephalosporin, it has been replaced by more modern agents. It remains available in some veterinary formulations for mastitis treatment in cattle.

分子量

445.4000 g/mol

TPSA

179.00 Ų

作用机制

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)OCC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)CSc3ccncc3)[C@H]2SC1.[Na+]

InChI

InChI=1S/C17H17N3O6S2.Na/c1-9(21)26-6-10-7-28-16-13(15(23)20(16)14(10)17(24)25)19-12(22)8-27-11-2-4-18-5-3-11;/h2-5,13,16H,6-8H2,1H3,(H,19,22)(H,24,25);/q;+1/p-1/t13-,16-;/m1./s1

Molecular Formula

C17H16N3NaO6S2

HBD / HBA

1 / 9

可旋转键数

8

重原子数

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

The sodium salt form of cephapirin was used parenterally for gram-positive bacterial infections and surgical prophylaxis in human medicine. As an early first-generation cephalosporin, it has been replaced by more modern agents. It remains available in some veterinary formulations for mastitis treatment in cattle.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Cephapirin Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201043. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23675312. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.